Graham Barker wrote to Liz Lynne MP drawing attention to the Government's reluctance to adopt the UKHCDO guidelines and highlighting the difference in approach in Scotland where all children with Haemophilia A had been transferred to recombinant plans, by 1997. Read more about Graham Barker wrote to Liz Lynne MP drawing attention to the Government's reluctance to adopt the UKHCDO guidelines and highlighting the difference in approach in Scotland where all children with Haemophilia A had been transferred to recombinant plans, by 1997.
Graham Barker, director of services and development at the Haemophilia Society, wrote a letter to Alf Morris MP indicating that some health authorities were refusing to pay the additional costs associated with recombinant Factor 8. Read more about Graham Barker, director of services and development at the Haemophilia Society, wrote a letter to Alf Morris MP indicating that some health authorities were refusing to pay the additional costs associated with recombinant Factor 8.
A panel established by the Board of the Newcastle upon Tyne Hospitals NHS Trust recommended to the Board that "it support the universal availability of recombinant Factor VIII. This recommendation should be conveyed to Health Authorities for funding". Read more about A panel established by the Board of the Newcastle upon Tyne Hospitals NHS Trust recommended to the Board that "it support the universal availability of recombinant Factor VIII. This recommendation should be conveyed to Health Authorities for funding".
The chair of the Haemophilia Society wrote to Stephen Dorrell reiterating the uneven availability of recombinant Factor 8 across the UK. Read more about The chair of the Haemophilia Society wrote to Stephen Dorrell reiterating the uneven availability of recombinant Factor 8 across the UK.
A Haemophilia Society Board of Trustees' meeting recorded the unequal availability of recombinant Factor 8 across the UK. Read more about A Haemophilia Society Board of Trustees' meeting recorded the unequal availability of recombinant Factor 8 across the UK.
The tax tribunal noted that recombinant had the advantages over blood-derived factor concentrate of being available in an unlimited supply, being a renewable source, and having freedom from blood-borne viral contamination. By comparison, purified plasma derived Factor 8 "might contain low levels of viral contamination." Read more about The tax tribunal noted that recombinant had the advantages over blood-derived factor concentrate of being available in an unlimited supply, being a renewable source, and having freedom from blood-borne viral contamination. By comparison, purified plasma derived Factor 8 "might contain low levels of viral contamination."
The tax tribunal gave a detailed judgment when upholding HMCE in deciding that the sale of recombinant was liable to VAT. It recorded findings of fact that recombinant was "now considered as the treatment of choice by most clinicians and by the Haemophilia Society." Read more about The tax tribunal gave a detailed judgment when upholding HMCE in deciding that the sale of recombinant was liable to VAT. It recorded findings of fact that recombinant was "now considered as the treatment of choice by most clinicians and by the Haemophilia Society."
HM Customs and Excise decided that recombinant Factor 8 could no longer be considered exempt from VAT because it was not a biological product. Read more about HM Customs and Excise decided that recombinant Factor 8 could no longer be considered exempt from VAT because it was not a biological product.
The parents of a child with haemophilia complained about the lack of recombinant Factor 8, even though the use of the product had been deemed "appropriate on clinical grounds" by the treating clinician. Read more about The parents of a child with haemophilia complained about the lack of recombinant Factor 8, even though the use of the product had been deemed "appropriate on clinical grounds" by the treating clinician.
John Horam replied to Baxter Healthcare Limited regarding the imposition of VAT on recombinant. Read more about John Horam replied to Baxter Healthcare Limited regarding the imposition of VAT on recombinant.